Why the FDA Tried to Ban This Amino Acid Derivative

The master antioxidant precursor you need to fend off sickness this winter

This isn’t coincidental timing.

Winter delivers the viral transmission trifecta: shorter days → minimal sun exposure → max indoor crowding. When infection rates spike, glutathione becomes your most critical defense. And NAC is the precursor that fuels it.

But immunity is only a single part of the NAC story. Its mechanisms extend to cognitive function, fertility, cardiovascular protection, & metabolic disease. 60+ years made it valuable enough for the FDA to remove it from the supplement market entirely.

Here’s everything you need to know about NAC benefits & protocols.

Why NAC Was Banned (Almost)

Relative to other compounds, NAC has a unique regulatory history spanning six decades:

• 1960: Zambon Group patents NAC as a mucolytic agent

• 1963: FDA approves NAC as prescription drug (Mucomyst) for respiratory mucus clearance

• 1967: NAC proven to replenish liver glutathione → becomes standard antidote for acetaminophen overdose

• 1991: First sold as OTC dietary supplement in the US

• 2004: FDA approves IV NAC (Acetadote) for acetaminophen overdose

• July 2020: FDA issues warning letters to 7 supplement companies, declaring NAC illegal as a dietary supplement under DSHEA’s “drug preclusion clause”

• May 2021: Amazon removes all 700+ NAC listings

• June 2021: Industry groups sue FDA in federal court

• April 2022: FDA issues draft guidance allowing enforcement discretion

• August 2022: FDA finalizes guidance; Amazon relists NAC products

• Today: Final FDA ruling still pending

How NAC Works

NAC’s Mechanisms of Action (Source)

Glutathione Precursor (Indirect Antioxidant Action)

The primary mechanism at play¹. NAC provides cysteine, the amino acid needed to synthesize glutathione (GSH) → the body’s primary intracellular antioxidant. Once absorbed, NAC breaks down to release cysteine combining with glutamate & glycine to form GSH.

A couple reasons this matters:

• Direct supplementation with cysteine or glutathione is ineffective for raising plasma GSH levels

• NAC is the most reliable method for boosting glutathione stores

Reactive Oxygen Species Scavenging (Direct Antioxidant Action)

NAC’s thiol (-SH) group directly neutralizes reactive oxygen species (ROS) including hydroxyl radicals and hydrogen peroxide. The thiol donates electrons to stabilize ROS preventing oxidative damage to proteins, lipids, and DNA.

Mucolytic Action

NAC breaks disulfide bonds in mucus glycoproteins → reduces mucus viscosity → improves airway clearance in both acute and chronic respiratory conditions.

Benefits: What the Research Shows

Immune Health

Flu Symptoms

6-month study (n=262)² : 1,200 mg/day NAC significantly reduced flu frequency, severity, & duration.

Frequency of flu-like symptoms over 6-month trial period

Only 25% of infected NAC users developed symptomatic illness vs. 79% in placebo. Even breakthrough infections were milder.

Types of symptoms manifested over 6-month trial period

COVID-19

2025 meta-analysis (12 RCTs, 1,100+ patients)³: NAC reduced mortality by 41% & accelerated hospital discharge rates.

A 2024 review⁴ also suggests NAC may function as a spike protein detox agent.

General Immune Function

4-month trial (n=36 postmenopausal women, 600 mg/day)⁵:

• Natural killer cell activity

  

  Natural killer cell activity before, 2, 3, & 4 months after NAC intervention

  • Age 50-69 years:

    • Baseline (prior to NAC): 22% lysis

    • 4 months: 50% lysis (+127% increase)

  • Age ≥70 years:

    • Baseline (prior to NAC): 15% lysis

    • 4 months: 42% lysis (+180% increase)

• Neutrophil phagocytosis → the ability of white blood cells to scavenge & destroy pathogens

  

  Neutrophil phagocytosis before, 2, 3, & 4 months after NAC intervention

  • Age 50-69 years:

    • Baseline (prior to NAC): 105 phagocytic index

    • 4 months: 220 phagocytic index (+110% increase)

  • Age ≥70 years:

    • Baseline (prior to NAC): 82 phagocytic index

    • 4 months: 195 phagocytic index (+138% increase)

• TNF-α → a pro-inflammatory cytokine associated with chronic inflammation

  • Age 50-69 years:

    • Baseline (prior to NAC): 1,100 pg/ml

    • 4 months: 780 pg/ml (-29% decrease)

  • Age ≥70 years:

    • Baseline (prior to NAC): 1,100 pg/ml

    • 4 months: 820 pg/ml (-25% decrease)

TNF-α before, 2, 3, & 4 months after NAC intervention

• Plasma MDA → a marker of lipid peroxidation & oxidative stress

  • Age 50-69 years:

    • Baseline (prior to NAC): 3.4 μM

    • 4 months: 2.3 μM (-32% decrease)

  • Age ≥70 years:

    • Baseline (prior to NAC): 4.2 μM

    • 4 months of NAC: 2.9 μM (-31% decrease)

Plasma MDA before, 2, 3, & 4 months after NAC intervention

Skin Health

Acne

8-week trial (n=56)⁶: NAC increased glutathione by 205%, reduced malondialdehyde by 39%, & decreased IL-8 by 72%. Inflammatory lesions reduced by 50% (placebo = no significant change).

Effects of NAC on the number of inflammatory lesions on half-face of patients

Respiratory Health

Bronchiectasis

12-month trial (n=161)⁷: 1,200 mg/day NAC reduced exacerbation rates by 34%, with 2x more patients remaining flare-up-free vs. standard treatment.

Reduction of disease worsening in NAC vs. placebo groups

COPD

2024 meta-analysis (7 studies)⁸: NAC reduced exacerbation rates by 19-24% and tripled the odds of improved respiratory symptoms and quality of life. Benefits were most pronounced in treatments exceeding 5 months.

Pneumonia

2021 RCT (n=82)⁹: 1,200 mg/day NAC prevented progression to severe respiratory failure & reduced mortality in hospitalized COVID-19 patients.

Progression to severe respiratory failure in NAC vs. placebo groups

It also cut mortality rates in hospitalized COVID-19 patients.

Mortality rates of COVID-19 patients in NAC vs. placebo groups

Cardiovascular Health

Cardiac Protection

Meta-analysis (28 RCTs, 2,174 patients)¹⁰: NAC administered before/during coronary reperfusion reduced postoperative atrial fibrillation risk by 43%. Effective across doses ranging from 20-150 mg/kg IV or 0.3-4.2 g oral.

Random effects model highlighting NAC’s impact vs. control group

Heart Failure

12-week RCT (n=55)¹¹: 1,200 mg/day NAC alongside standard therapy improved markers of systolic heart failure.

Metabolic Health

12-week RCT (n=76)¹²: 1,800 mg/day NAC significantly improved:

• Fasting blood glucose ↓

Fasting blood glucose following 12-week intervention for placebo vs. NAC groups

• Fasting insulin ↓

  

  Fasting insulin following 12-week intervention for placebo vs. NAC groups

• HOMA-IR ↓

  

  Insulin resistance following 12-week intervention for placebo vs. NAC groups

• HDL-C ↑

  

  HDL-C following 12-week intervention for placebo vs. NAC groups

• hs-CRP ↓

  

  hs-CRP following 12-week intervention for placebo vs. NAC groups

• Total plasma glutathione ↑

  

  Plasma glutathione (master antioxidant) following 12-week intervention for placebo vs. NAC groups

Liver Function

3-month RCT (n=30)¹³: NAC significantly outperformed vitamin C across all grades of steatosis:

• ALT reduced by 33%

  

  ALT trend during 3-month intervention for NAC group

• Spleen size reduced by 4%

Spleen size trend during 3-month intervention for NAC group

Anti-Inflammatory & Antioxidant Effects

2020 meta-analysis (28 studies)¹⁴: NAC at doses ranging from 500-2,000 mg/day significantly reduced:

• Malondialdehyde (lipid peroxidation)

• IL-8

• Homocysteine

Sexual & Reproductive Health

Male Fertility

Meta-analysis (5 studies)¹⁵: NAC at 600 mg/day significantly improved all major semen parameters:

• Sperm volume ↑

  

  Sperm volume effects of NAC vs. control

• Sperm concentration ↑

  

  Sperm concentration effects of NAC vs. control

• Sperm motility ↑

  

  Sperm motility effects of NAC vs. control

• Sperm morphology ↑

  

  Sperm morphology effects of NAC vs. control

PCOS

2025 meta-analysis (2,515 subjects)¹⁶ : 600 mg 3x/day NAC significantly increased:

• Progesterone levels ↑

• Endometrial thickness ↑

• Luteinizing hormone ↑

Gut Health

Ulcerative Colitis

22-week trial (n=168)¹⁷: 800 mg/day NAC resulted in 68% reduction in relapses (6 vs. 19 in placebo). Also significantly lowered hs-CRP.

H. pylori

RCT (n=40)¹⁸: NAC pretreatment of 600 mg/day tripled eradication rates in treatment-resistant patients (65% success vs. 20% without NAC). NAC disrupts the protective biofilm that shields H. pylori from antibiotics.

(A) Scanning electron micrograph showing the gastric mucosal surface densely covered by a thick H. pylori biofilm prior to treatment. (B) Complete disappearance of the biofilm from the gastric mucosa following successful H. pylori eradication.

Brain, Cognitive, & Neurological Health

Depression/Bipolar Disorder

2024 meta-analysis (900 subjects)¹⁹: 1,000-3,000 mg/day NAC for 8-24 weeks significantly reduced depressive symptoms.

Schizophrenia

2020 meta-analysis (7 studies; 440 subjects)²⁰: 1,200-3,600 mg/day for 24 weeks improved overall symptom severity & cognitive function.

NAC total treatment effectiveness scores

Cannabis Use

RCT (n=116 adolescents)²¹: 1,200 mg 2x/day + counseling resulted in 2.5x higher odds of abstinence vs. placebo over 8 weeks. First successful pharmacotherapy trial for cannabis dependence in any age group.

Proportion of negative urine CBD tests during the 8-week trial

Neurodegenerative Disease

3-month RCT²²: Weekly IV NAC (50 mg/kg) + 1,000 mg/day oral NAC showed 3.4-8.3% increase in dopamine transporter binding.

Autism

2023 meta-analysis²³: 2,400 mg/day NAC for 8-12 weeks showed significant improvements in:

• Overall aberrant behavior

• Irritability

• Hyperactivity

• Social awareness

Protocols

Objective-Driven Protocols

Phys Current Protocol

Objectives:

• Immunity

• Brain Health

Daily Dose: 1,200 mg — split across 2 doses (upon waking & 1 hr before bed)

Optimal Timing: NAC is best taken on an empty stomach to optimize absorption & bioavailability. High-fat or protein-dense meals slow gastric transit → prolong the time NAC spends in the acidic stomach environment → greater susceptibility to degradation.

Why the AM dose? → Glutathione levels naturally peak²⁴ in early morning to handle daily oxidative stress. Taking NAC on an empty stomach in the morning amplifies this peak providing immediate cysteine for glutathione synthesis.

Glutathione levels in human platelets over 24-hr period

Why the PM dose? → Glutathione dips at night during cellular repair & detox. Pre-bed NAC replenishes cysteine for nocturnal production supporting liver detox & neuroprotection during sleep.

Cycling Protocol: NAC should be cycled. As the winter season picks up → temperatures start to drop → more time indoors → higher susceptibility to infection, I begin to cycle 1,200 mg across 2 daily doses for antioxidant support.

Reputable Source

Nootropics Depot NAC is my go-to choice.

✅ Third-party tested for purity, potency, & heavy metals (COA available on every batch)

✅ Pure powder format (no fillers, binders, or unnecessary additives → available in capsules)

✅ No sulfur odor (common in NAC products)

✅ Pharmaceutical-grade manufacturing

✅ $0.07/Serving

---

Another cost-effective tool to add to your immunity arsenal this winter. Stay healthy — it’s been a nasty winter this year. And until next time.

Your friend,
Phys

1. Tenório MCDS, Graciliano NG, Moura FA, Oliveira ACM, Goulart MOF. N-Acetylcysteine (NAC): Impacts on Human Health. Antioxidants (Basel). 2021 Jun 16;10(6):967. doi: 10.3390/antiox10060967. PMID: 34208683; PMCID: PMC8234027.

2. De Flora S, Grassi C, Carati L. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J. 1997 Jul;10(7):1535-41. doi: 10.1183/09031936.97.10071535. PMID: 9230243.

3. Varikasuvu SR, Manne M, Kumar S, Mudgal SK, Raj V, Varshney S, Gupta P, Grover A, Goyal C, Lal V, Singh H, Lisa M, Saransh Workshop Members. COVID-19 clinical outcomes and N-acetylcysteine (CoViNAC study): a GRADE compliant meta-analysis of randomized controlled trials with molecular docking and dynamics simulation studies with Mpro of SARS-CoV-2. Cell Mol Biol (Noisy-le-grand). 2025 May 26;71(5):95-102. doi: 10.14715/cmb/2025.71.5.13. PMID: 40418545.

4. Debnath U, Mitra A, Dewaker V, Prabhakar YS, Tadala R, Krishnan K, Wagh P, Velusamy U, Baliyan A, Kurpad AV, Bhattacharyya P, Mandal AK. Conformational perturbation of SARS-CoV-2 spike protein using N-acetyl cysteine: an exploration of probable mechanism of action to combat COVID-19. J Biomol Struct Dyn. 2024 Jul;42(10):5042-5052. doi: 10.1080/07391102.2023.2234031. Epub 2023 Jul 21. PMID: 37477247.

5. Arranz L, Fernández C, Rodríguez A, Ribera JM, De la Fuente M. The glutathione precursor N-acetylcysteine improves immune function in postmenopausal women. Free Radic Biol Med. 2008 Nov 1;45(9):1252-62. doi: 10.1016/j.freeradbiomed.2008.07.014. Epub 2008 Jul 27. PMID: 18694818.

6. Sahib AS, Al-Anbari HH, Salih M, Abdullah F (2012) Effects of Oral Antioxidants on Lesion Counts Associated with Oxidative Stress and Inflammation in Patients with Papulopustular Acne. J Clin Exp Dermatol Res 3:163. doi:10.4172/2155-9554.1000163

7. Qi Q, Ailiyaer Y, Liu R, Zhang Y, Li C, Liu M, Wang X, Jing L, Li Y. Effect of N-acetylcysteine on exacerbations of bronchiectasis (BENE): a randomized controlled trial. Respir Res. 2019 Apr 11;20(1):73. doi: 10.1186/s12931-019-1042-x. PMID: 30975143; PMCID: PMC6458826.

8. Papi A, Alfano F, Bigoni T, Mancini L, Mawass A, Baraldi F, Aljama C, Contoli M, Miravitlles M. N-acetylcysteine Treatment in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis/Pre-COPD: Distinct Meta-analyses. Arch Bronconeumol. 2024 May;60(5):269-278. English, Spanish. doi: 10.1016/j.arbres.2024.03.010. Epub 2024 Mar 18. PMID: 38555190.

9. Assimakopoulos SF, Aretha D, Komninos D, Dimitropoulou D, Lagadinou M, Leonidou L, Oikonomou I, Mouzaki A, Marangos M. N-acetyl-cysteine reduces the risk for mechanical ventilation and mortality in patients with COVID-19 pneumonia: a two-center retrospective cohort study. Infect Dis (Lond). 2021 Nov;53(11):847-854. doi: 10.1080/23744235.2021.1945675. Epub 2021 Jun 29. PMID: 34182881.

10. Khan SA, Campbell AM, Lu Y, An L, Alpert JS, Chen QM. N-Acetylcysteine for Cardiac Protection During Coronary Artery Reperfusion: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Cardiovasc Med. 2021 Nov 19;8:752939. doi: 10.3389/fcvm.2021.752939. PMID: 34869660; PMCID: PMC8640098.

11. Yazdi A, Khansari N, Mehrpooya M, Mohammadi Y, Zareie S. Oral N-acetylcysteine as an adjunct to standard medical therapy improved heart function in cases with stable class II and III systolic heart failure. Ir J Med Sci. 2022 Oct;191(5):2063-2075. doi: 10.1007/s11845-021-02829-3. Epub 2021 Nov 2. PMID: 34727343.

12. Panahi, Y., Ostadmohammadi, V., Raygan, F., Sharif, M. R., & Sahebkar, A. (2022). The effects of N-acetylcysteine administration on metabolic status and serum adiponectin levels in patients with metabolic syndrome: A randomized, double-blind, placebo-controlled trial. Journal of Functional Foods, 99, 105299. doi:10.1016/j.jff.2022.105299

13. Khoshbaten M, Aliasgarzadeh A, Masnadi K, Tarzamani MK, Farhang S, Babaei H, Kiani J, Zaare M, Najafipoor F. N-acetylcysteine improves liver function in patients with non-alcoholic Fatty liver disease. Hepat Mon. 2010 Winter;10(1):12-6. Epub 2010 Mar 1. PMID: 22308119; PMCID: PMC3270338.

14. Faghfouri AH, Zarezadeh M, Tavakoli-Rouzbehani OM, Radkhah N, Faghfuri E, Kord-Varkaneh H, Tan SC, Ostadrahimi A. The effects of N-acetylcysteine on inflammatory and oxidative stress biomarkers: A systematic review and meta-analysis of controlled clinical trials. Eur J Pharmacol. 2020 Oct 5;884:173368. doi: 10.1016/j.ejphar.2020.173368. Epub 2020 Jul 26. PMID: 32726657.

15. Syarif S, Makkaraka MAG, Zainal ATF, Birowo P, Atmoko W. Unlocking the potential of antioxidant supplementation with n-acetylcysteine to improve seminal parameters and analysis of its safety: a systematic review and meta-analysis of randomized controlled trials. Arch Ital Urol Androl. 2025 Mar 28;97(1):13750. doi: 10.4081/aiua.2025.13750. Epub 2025 Mar 24. PMID: 40126496.

16. Viña I, Viña JR, Carranza M, Mariscal G. Efficacy of N-Acetylcysteine in Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis. Nutrients. 2025 Jan 14;17(2):284. doi: 10.3390/nu17020284. PMID: 39861414; PMCID: PMC11768055.

17. Masnadi Shirazi K, Sotoudeh S, Masnadi Shirazi A, Moaddab SY, Nourpanah Z, Nikniaz Z. Effect of N-acetylcysteine on remission maintenance in patients with ulcerative colitis: A randomized, double-blind controlled clinical trial. Clin Res Hepatol Gastroenterol. 2021 Jul;45(4):101532. doi: 10.1016/j.clinre.2020.08.010. Epub 2020 Oct 14. PMID: 33067169.

18. Cammarota G, Branca G, Ardito F, Sanguinetti M, Ianiro G, Cianci R, Torelli R, Masala G, Gasbarrini A, Fadda G, Landolfi R, Gasbarrini G. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clin Gastroenterol Hepatol. 2010 Sep;8(9):817-820.e3. doi: 10.1016/j.cgh.2010.05.006. Epub 2010 May 31. PMID: 20478402.

19. Peng TR, Lin HH, Tseng TL, Huang YH, Tsai PY, Lin CY, Lee MC, Chen SM. Efficacy of N-acetylcysteine for patients with depression: An updated systematic review and meta-analysis. Gen Hosp Psychiatry. 2024 Nov-Dec;91:151-159. doi: 10.1016/j.genhosppsych.2024.10.018. Epub 2024 Nov 3. PMID: 39504621.

20. Yolland CO, Hanratty D, Neill E, Rossell SL, Berk M, Dean OM, Castle DJ, Tan EJ, Phillipou A, Harris AW, Barreiros AR, Hansen A, Siskind D. Meta-analysis of randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia. Aust N Z J Psychiatry. 2020 May;54(5):453-466. doi: 10.1177/0004867419893439. Epub 2019 Dec 11. PMID: 31826654.

21. Gray KM, Carpenter MJ, Baker NL, DeSantis SM, Kryway E, Hartwell KJ, McRae-Clark AL, Brady KT. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry. 2012 Aug;169(8):805-12. doi: 10.1176/appi.ajp.2012.12010055. Erratum in: Am J Psychiatry. 2012 Aug 1;169(8):869. PMID: 22706327; PMCID: PMC3410961.

22. Monti DA, Zabrecky G, Kremens D, Liang TW, Wintering NA, Bazzan AJ, Zhong L, Bowens BK, Chervoneva I, Intenzo C, Newberg AB. N-Acetyl Cysteine Is Associated With Dopaminergic Improvement in Parkinson’s Disease. Clin Pharmacol Ther. 2019 Oct;106(4):884-890. doi: 10.1002/cpt.1548. Epub 2019 Jul 17. PMID: 31206613.

23. Lee TM, Lee KM, Lee CY, Lee HC, Tam KW, Loh EW. Effectiveness of N-acetylcysteine in autism spectrum disorders: A meta-analysis of randomized controlled trials. Aust N Z J Psychiatry. 2021 Feb;55(2):196-206. doi: 10.1177/0004867420952540. Epub 2020 Sep 8. PMID: 32900213.

24. Radha E, Hill TD, Rao GH, White JG. Glutathione levels in human platelets display a circadian rhythm in vitro. Thromb Res. 1985 Dec 15;40(6):823-31. doi: 10.1016/0049-3848(85)90319-6. PMID: 4089839.